316 related articles for article (PubMed ID: 17355491)
1. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval.
Sulak P; Willis S; Kuehl T; Coffee A; Clark J
Headache; 2007 Jan; 47(1):27-37. PubMed ID: 17355491
[TBL] [Abstract][Full Text] [Related]
2. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
Coffee AL; Kuehl TJ; Willis S; Sulak PJ
Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986
[TBL] [Abstract][Full Text] [Related]
3. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen.
Coffee AL; Sulak PJ; Kuehl TJ
Contraception; 2007 Jun; 75(6):444-9. PubMed ID: 17519150
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
5. Comparison of scales for evaluating premenstrual symptoms in women using oral contraceptives.
Coffee AL; Kuehl TJ; Sulak PJ
Pharmacotherapy; 2008 May; 28(5):576-83. PubMed ID: 18447656
[TBL] [Abstract][Full Text] [Related]
6. Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen.
Sulak PJ; Kuehl TJ; Coffee A; Willis S
Am J Obstet Gynecol; 2006 Oct; 195(4):935-41. PubMed ID: 16647684
[TBL] [Abstract][Full Text] [Related]
7. Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive.
Kaunitz AM; Portman DJ; Hait H; Reape KZ
Contraception; 2009 May; 79(5):350-5. PubMed ID: 19341846
[TBL] [Abstract][Full Text] [Related]
8. Pituitary-ovarian hormone levels and symptoms in oral contraceptive users: comparison of a 21/7-day and extended regimen.
Kuehl TJ; Speikermann AM; Willis SA; Coffee A; Sulak PJ
J Reprod Med; 2008 Apr; 53(4):266-70. PubMed ID: 18472649
[TBL] [Abstract][Full Text] [Related]
9. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 microg and ethinylestradiol 15 microg (Minesse).
Barbosa IC; Filho CI; Faggion D; Baracat EC
Contraception; 2006 Jan; 73(1):30-3. PubMed ID: 16371291
[TBL] [Abstract][Full Text] [Related]
10. A prospective follow-up of two 21/7 cycles followed by two extended regimen 84/7 cycles with contraceptive pills containing ethinyl estradiol and drospirenone.
Seidman DS; Yeshaya A; Ber A; Amodai I; Feinstein I; Finkel I; Gordon N; Porat N; Samuel D; Shiran-Makler E; Wolman I
Isr Med Assoc J; 2010 Jul; 12(7):400-5. PubMed ID: 20862819
[TBL] [Abstract][Full Text] [Related]
11. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA
Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962
[TBL] [Abstract][Full Text] [Related]
12. A look at the long-term safety of an extended-regimen OC.
Davis MG; Reape KZ; Hait H
J Fam Pract; 2010 May; 59(5):E3. PubMed ID: 20544040
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
[TBL] [Abstract][Full Text] [Related]
14. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial.
Davis AR; Westhoff C; O'Connell K; Gallagher N
Obstet Gynecol; 2005 Jul; 106(1):97-104. PubMed ID: 15994623
[TBL] [Abstract][Full Text] [Related]
15. Effects of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use.
Sänger N; Stahlberg S; Manthey T; Mittmann K; Mellinger U; Lange E; Kuhl H; Wiegratz I
Contraception; 2008 Jun; 77(6):420-5. PubMed ID: 18477491
[TBL] [Abstract][Full Text] [Related]
16. Extended cycle combined oral contraceptives and prophylactic frovatriptan during the hormone-free interval in women with menstrual-related migraines.
Coffee AL; Sulak PJ; Hill AJ; Hansen DJ; Kuehl TJ; Clark JW
J Womens Health (Larchmt); 2014 Apr; 23(4):310-7. PubMed ID: 24450487
[TBL] [Abstract][Full Text] [Related]
17. The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days.
Foidart JM; Sulak PJ; Schellschmidt I; Zimmermann D;
Contraception; 2006 Jan; 73(1):34-40. PubMed ID: 16371292
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
Aurora SK; Gawel M; Brandes JL; Pokta S; Vandenburgh AM;
Headache; 2007 Apr; 47(4):486-99. PubMed ID: 17445098
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
[TBL] [Abstract][Full Text] [Related]
20. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial.
Freitag F; Smith T; Mathew N; Rupnow M; Greenberg S; Mao L; Finlayson G; Wright P; Biondi D;
Headache; 2008 Mar; 48(3):341-54. PubMed ID: 18302700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
